Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVNNASDAQ:LNTHNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$19.81-15.4%$26.44$15.79▼$55.70$2.02B1.331.13 million shs6.16 million shsLNTHLantheus$101.77-1.8%$97.37$65.76▼$126.89$6.97B0.2955,167 shs644,509 shsROIVRoivant Sciences$11.01+0.1%$10.34$8.73▼$13.06$7.86B1.255.46 million shs8.02 million shsRVMDRevolution Medicines$38.77+0.5%$37.43$29.17▼$62.40$7.21B1.371.43 million shs1.08 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven0.00%-2.95%-30.15%-49.68%-48.82%LNTHLantheus0.00%+0.44%+4.87%+4.38%+56.07%ROIVRoivant Sciences0.00%+8.47%+5.06%-1.43%+1.01%RVMDRevolution Medicines0.00%+5.47%+1.76%-5.42%+8.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven3.5966 of 5 stars4.51.00.00.03.14.20.6LNTHLantheus4.4292 of 5 stars3.51.00.04.23.52.51.9ROIVRoivant Sciences1.9239 of 5 stars3.51.00.00.02.72.50.0RVMDRevolution Medicines3.7914 of 5 stars3.50.00.04.73.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$62.77216.94% UpsideLNTHLantheus 3.00Buy$129.4327.18% UpsideROIVRoivant Sciences 3.00Buy$17.5058.95% UpsideRVMDRevolution Medicines 3.00Buy$66.6771.95% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, ROIV, LNTH, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.003/20/2025BHVNBiohavenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/7/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$69.00 ➝ $63.003/5/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$72.00 ➝ $68.003/4/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/4/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ALNTHLantheus$1.53B4.54$8.49 per share11.98$11.91 per share8.54ROIVRoivant Sciences$122.59M64.09N/AN/A$7.76 per share1.42RVMDRevolution Medicines$742K9,714.08N/AN/A$11.09 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$408.17M-$9.39N/AN/AN/AN/A-225.12%-158.89%5/8/2025 (Estimated)LNTHLantheus$326.66M$4.3716.9316.13N/A28.57%44.29%23.52%5/7/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/6/2025 (Estimated)Latest BHVN, ROIV, LNTH, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/8/2025Q1 2025BHVNBiohaven-$1.64N/AN/AN/A$1.25 millionN/A5/7/2025Q1 2025LNTHLantheus$1.64N/AN/AN/A$377.37 millionN/A3/3/2025Q4 2024BHVNBiohaven-$1.56-$1.85-$0.29-$1.85$100.00 millionN/A2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohavenN/A2.892.89LNTHLantheusN/A1.651.56ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%LNTHLantheus99.06%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%LNTHLantheus2.00%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239102.07 million84.94 millionOptionableLNTHLantheus70068.48 million68.48 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250185.91 million154.76 millionOptionableBHVN, ROIV, LNTH, and RVMD HeadlinesRecent News About These CompaniesHood River Capital Management LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 25 at 7:19 AM | marketbeat.comRock Springs Capital Management LP Grows Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comWells Fargo & Company MN Has $3.86 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Barclays PLCApril 22, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Nan Fung Group Holdings LtdApril 21, 2025 | marketbeat.comAltium Capital Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 20, 2025 | marketbeat.comMarshall Wace LLP Acquires 439,802 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 20, 2025 | marketbeat.comWalleye Capital LLC Sells 111,076 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 18, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Recommendation of "Buy" from BrokeragesApril 14, 2025 | marketbeat.comFmr LLC Has $294.90 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 13, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Alliancebernstein L.P.April 13, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comADAR1 Capital Management LLC Has $7.44 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)April 9, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Stake Decreased by Finepoint Capital LPApril 8, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Geode Capital Management LLCApril 8, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Hits New 1-Year Low - Here's WhyApril 7, 2025 | marketbeat.comExodusPoint Capital Management LP Acquires Shares of 123,315 Revolution Medicines, Inc. (NASDAQ:RVMD)April 7, 2025 | marketbeat.comCalifornia Public Employees Retirement System Has $11.74 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)April 7, 2025 | marketbeat.com75,000 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Pamalican Asset Management LtdApril 6, 2025 | marketbeat.comRevolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual MeetingApril 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, ROIV, LNTH, and RVMD Company DescriptionsBiohaven NYSE:BHVN$19.80 -3.60 (-15.36%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$19.88 +0.07 (+0.35%) As of 04/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Lantheus NASDAQ:LNTH$101.77 -1.87 (-1.80%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$102.24 +0.48 (+0.47%) As of 04/25/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$11.01 +0.01 (+0.09%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$11.14 +0.13 (+1.18%) As of 04/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$38.77 +0.19 (+0.49%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$39.50 +0.73 (+1.89%) As of 04/25/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
